Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity
Karam L., Mabilleau G., Paccou J.
Narrative Review, published in Osteoporos Int (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Osteoporos Int (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40920189
- PMCID
- PMC12628458
- DOI
- 10.1007/s00198-025-07664-1
- Citations
- 1
Abstract (original English)
Medications like liraglutide 3.0 mg daily (Saxenda®; Novo Nordisk) and semaglutide 2.4 mg weekly (Wegovy®; Novo Nordisk), which are glucagon-like peptide-1 receptor agonists (GLP-1Ra), have been sanctioned for prolonged weight management in people living with obesity (PwO). Although GLP-1 might enhance bone metabolism and quality, the impact of these receptor agonists on bone health remains uncertain and is the subject of this review. Data on bone health in the context of calorie restriction and bariatric surgery were also summarized. A comprehensive search of the literature on preclinical studies and human data published in English was performed from Jan 2013 to Dec 2024 to identify the various effects of GLP-1Ra on bone health. The effects of intentional weight loss procedures in PwO are well documented; significant weight reduction (~ 7-10%) through calorie restriction, with or without exercise, and bariatric/metabolic surgery results in high turnover bone loss. In different rodent models, liraglutide seems to positively influence bone material properties despite notable weight loss. However, the most favorable effects on bone mineral density and microarchitecture were noted at concentrations much higher than those approved for human obesity treatment. Current evidence on the effects of GLP-1Ra on bone health in PwO is limited. Although initial findings suggest that GLP-1Ra
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.